Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Covid save search
Genetic Technologies Provides Update on COVID-19 Disease Severity Test
Published: 2020-07-15 (Crawled : 22:16) - globenewswire.com
GENE | News 0 d | $2.27 -6.97% -7.49% 64K
|
Health Technology
|
| O: 22.57%
H: 271.84%
C: 104.69%
covid test disease technology covid-19
Precipio Launches its Rapid COVID-19 Antibody test on Amazon Platform
Published: 2021-05-03 (Crawled : 14:00) - globenewswire.com
PRPO A | $6.72 0.07% 1.7K
|
Health Technology
|
| O: 1.1%
H: 169.02%
C: 169.02%
covid test antibody amazon covid-19
Gritstone Advances Second Generation COVID-19 Vaccine “CORAL” Program with Support from NIAID; Program has Potential to Protect Against Mutant Variants of SARS-CoV-2
Published: 2021-01-19 (Crawled : 11:01) - globenewswire.com
GRTS | $0.7414 -0.31% -0.31% 1.5M
|
Health Technology
|
| O: 38.34%
H: 154.19%
C: 151.92%
covid vaccine potential sars-cov-2 program
Therapeutic Solutions International Awarded Landmark Patent for Cancer and COVID-19 Treatment
Published: 2021-12-28 (Crawled : 22:00) - biospace.com/
TSOI | $0.0007 0.0% 33M
|
Manufacturing
|
| O: -1.44%
H: 139.02%
C: 138.54%
covid-19 treatment patent covid cancer
U.S. FDA Lists Applied DNA’s Linea™ COVID-19 Assay Kit as 1 of Only 2 EUA-Authorized Tests Able to Detect S-Gene Mutation Found in SARS-CoV-2 U.K. Variant (B.1.1.7)
Published: 2021-01-08 (Crawled : 01:00) - biospace.com/
APDN | $0.3396 0.59% 0.59% 85K
|
Commercial Services
|
| O: 0.53%
H: 116.29%
C: 103.85%
covid test fda authorized sars-cov-2
Lilly, Vir Biotechnology and GSK Announce First Patient Dosed in Expanded BLAZE-4 Trial Evaluating Bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19
Published: 2021-01-27 (Crawled : 12:00) - globenewswire.com
GSK | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -1.12%
H: 0.1%
C: -1.6%
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.78%
H: 0.45%
C: -1.66%
VIR | $7.96 0.0% 1.1M
|
Health Technology
|
| O: -7.13%
H: 96.21%
C: 15.59%
covid ev biotech trial
Gritstone and Genevant Sciences Announce License Agreement for COVID-19 Vaccine
Published: 2021-01-20 (Crawled : 13:02) - globenewswire.com
GRTS | $0.7414 -0.31% -0.31% 1.5M
|
Health Technology
|
| O: -13.34%
H: 82.38%
C: 32.07%
covid vaccine license covid-19
Jaguar Health Announces Plan to Develop and Commercialize Crofelemer, the Company's Novel Proprietary Drug, for the Indication of Inflammatory Diarrhea, Initially in 'Long-Hauler' COVID-19 Recovery Patients
Published: 2020-11-30 (Crawled : 17:31) - jaguarhealth.gcs-web.com
JAGX | $0.158 -10.79% -12.09% 30M
|
Health Technology
|
| O: 2.14%
H: 81.82%
C: 63.12%
covid drug diarrhea commercialization crofelemer
Ocugen and Bharat Biotech to Co-Develop COVAXIN™, a Whole-Virion Inactivated COVID-19 Vaccine, for the US Market
Published: 2020-12-22 (Crawled : 13:00) - globenewswire.com
OCGN | News A | $1.315 -0.38% -0.38% 6.5M
|
Health Technology
|
| O: 60.82%
H: 75.55%
C: 70.3%
covid biotech vaccine
TYME Granted U.S. Patent Claims Covering Use of TYME-19 to Treat COVID-19 Infections
Published: 2021-02-03 (Crawled : 16:00) - biospace.com/
TYME | $0.3107 -8.21%
|
Health Technology
|
| O: 66.48%
H: 64.69%
C: 16.5%
covid patent granted injection covid-19 grant infections
Adamis Pharmaceuticals Announces IND Submission to FDA for Tempol for the Treatment of COVID-19
Published: 2021-01-20 (Crawled : 14:04) - globenewswire.com
ADMP | $0.7751 0.86% 2.6% 120K
|
Health Technology
|
| O: 27.7%
H: 61.48%
C: 39.11%
covid fda submission treatment covid-19
Todos Medical Supports Long COVID Awareness Day
Published: 2023-03-15 (Crawled : 19:00) - globenewswire.com
TOMDF | $0.0001 100.0% 14M
|
Manufacturing
|
| O: -33.33%
H: 60.0%
C: 30.0%
day covid medical
Dynavax and CEPI Announce $99 Million in Funding for CpG 1018 Adjuvant Manufacturing to Support the Global COVID-19 Response
Published: 2021-02-01 (Crawled : 14:00) - biospace.com/
DVAX | $11.78 3.88% 3.74% 9.3M
|
Health Technology
|
| O: 16.8%
H: 58.62%
C: 39.35%
covid response
Dynavax Announces Exercise of Option to Reserve Additional CpG 1018 to Produce 40 Million Doses of Valneva's Inactivated, Adjuvanted COVID-19 Vaccine Candidate for the UK Government
Published: 2021-02-01 (Crawled : 14:00) - biospace.com/
DVAX | $11.78 3.88% 3.74% 9.3M
|
Health Technology
|
| O: 16.8%
H: 58.62%
C: 39.35%
covid vaccine
Sorrento Announces Positive Preliminary Results of Phase 1b Study of COVI-MSC™ for Treatment of ICU COVID-19 Patients
Published: 2021-01-27 (Crawled : 01:00) - globenewswire.com
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 3.07%
H: 58.57%
C: 41.81%
covid positive results treatment phase 1b phase 2b
NRx Pharmaceuticals Announces First Successful Commercial Formulation for ZYESAMI™ (aviptadil), Enabling Volume Manufacture, Shipping, and Stockpiling of COVID-19 Medication Subject to Regulatory Approval
Published: 2021-07-22 (Crawled : 12:00) - biospace.com/
NRXP 1 d | $3.08 1.99% 1.95% 230K
|
Manufacturing
|
| O: 15.43%
H: 56.64%
C: 40.96%
covid approval aviptadil commercialization
eFFECTOR Therapeutics Announces Positive Top-Line Results from Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID
Published: 2023-02-21 (Crawled : 15:00) - globenewswire.com
EFTR | $1.645 -7.58% -8.21% 200K
|
|
| O: -42.99%
H: 54.67%
C: 43.67%
treatment covid trial therapeutics positive
Applied DNA Awarded CUNY COVID-19 Testing Contract
Published: 2021-08-03 (Crawled : 19:00) - adnas.com
APDN | $0.3396 0.59% 0.59% 85K
|
Commercial Services
|
| O: -0.92%
H: 46.47%
C: 26.58%
covid test contract covid-19 awards
NRx Pharmaceuticals Announces Positive Safety Report for ZYESAMI™ (aviptadil) in NIH Sponsored ACTIV-3 Critical Care Study in Patients with Life-Threatening COVID-19
Published: 2021-08-18 (Crawled : 16:00) - prnewswire.com
NRXP 1 d | $3.08 1.99% 1.95% 230K
|
Manufacturing
|
| O: 0.24%
H: 46.4%
C: 11.52%
covid positive aviptadil
Aditxt, Inc. Signs Letter of Intent for Exclusive Rights to Negotiate the Acquisition of a Biopharmaceutical Company Commercializing and Distributing Antiviral Oral Therapy for COVID-19
Published: 2021-08-25 (Crawled : 14:00) - biospace.com/
ADTX | $2.31 -4.15% -4.33% 15K
|
Health Technology
|
| O: 40.4%
H: 42.09%
C: 9.35%
covid biopharma acquisition therapy antiviral
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.